Abstract:In eukaryotic cells, the ubiquitin–proteasome system (UPS) plays a crucial role in selectively breaking down specific proteins. The ability of the UPS to target proteins effectively and expedite their removal has significantly contributed to the evolution of UPS-based targeted protein degradation (TPD) strategies. In particular, proteolysis targeting chimeras (PROTACs) are an immensely promising tool due to their high efficiency, extensive target range, and negligible drug resistance. This breakthrough has overcome the limitations posed by traditionally "non-druggable" proteins. However, their high molecular weight and constrained solubility impede the delivery of PROTACs. Fortunately, the field of nanomedicine has experienced significant growth, enabling the delivery of PROTACs through nanoscale drug-delivery systems, which effectively improves the stability, solubility, drug distribution, tissue-specific accumulation, and stimulus-responsive release of PROTACs. This article reviews the mechanism of action attributed to PROTACs and their potential implications for clinical applications. Moreover, we present strategies involving nanoplatforms for the effective delivery of PROTACs and evaluate recent advances in targeting nanoplatforms to the UPS. Ultimately, an assessment is conducted to determine the feasibility of utilizing PROTACs and nanoplatforms for UPS-based TPD. The primary aim of this review is to provide innovative, reliable solutions to overcome the current challenges obstructing the effective use of PROTACs in the management of cancer, neurodegenerative diseases , and metabolic syndrome. Therefore, this is a promising technology for improving the treatment status of major diseases.

Targeting UBE2C for Degradation by Bioprotacs Based on Bacterial E3 Ligase

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

IN SILICO DESIGN AND BINDING MECHANISM OF E3 LIGASE UBR1 RECRUITERS

Targeted protein degradation: expanding the toolbox

Discovery of E3 Ligase Ligands for Target Protein Degradation

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

Proteolysis targeting peptide (PROTAP) strategy for protein ubiquitination and degradation.

Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Advancing targeted protein degradation for cancer therapy

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

Targeting the Ubiquitin Pathway for Cancer Treatment

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system